- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | GRI Bio, Inc.: GRI Bio Featured in "Why Now" On-Demand Video Webcast | 2 | GlobeNewswire (USA) | ||
| Mo | GRI Bio to present Phase 2a IPF drug data at ERS Congress | 2 | Investing.com | ||
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| Mo | GRI Bio präsentiert Phase-2a-Studiendaten zu Lungenfibrose-Wirkstoff auf ERS-Kongress | 10 | Investing.com Deutsch | ||
| Mo | GRI Bio, Inc.: GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | 1 | GlobeNewswire (USA) | ||
| 14.08. | GRI Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.06. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.06. | GRI Bio receives orphan drug status for IPF treatment | 2 | Investing.com | ||
| 18.06. | GRI Bio, Inc.: GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | 353 | GlobeNewswire (Europe) | Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:... ► Artikel lesen | |
| 18.05. | GRI Bio, Inc.: GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase | 4 | GlobeNewswire (USA) | ||
| 14.05. | GRI Bio reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | GRI Bio reports phase 2a data for IPF drug candidate GRI-0621 | 2 | Investing.com | ||
| 14.05. | GRI Bio, Inc.: GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline | 354 | GlobeNewswire (Europe) | Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities... ► Artikel lesen | |
| 14.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | GRI Bio, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.04. | GRI Bio, Inc.: GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions | 1 | GlobeNewswire (USA) | ||
| 04.02. | GRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | 321 | GlobeNewswire (Europe) | Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations... ► Artikel lesen | |
| 28.01. | GRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | 296 | GlobeNewswire (Europe) | Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio"... ► Artikel lesen | |
| 21.01. | GRI Bio, Inc.: GRI Bio Announces Reverse Stock Split | 611 | GlobeNewswire (Europe) | GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company")... ► Artikel lesen | |
| 12.12.25 | GRI Bio, Inc.: GRI Bio Announces Closing of $8.0 Million Public Offering | 224 | GlobeNewswire (Europe) | LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell... ► Artikel lesen | |
| 10.12.25 | GRI Bio, Inc.: GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 274 | GlobeNewswire (Europe) | Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| DEFENCE THERAPEUTICS | 0,317 | -3,94 % | Defence Therapeutics Inc.: Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs | Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,36 | -3,30 % | Could Arrowhead Pharmaceuticals (ARWR)'s Plozasiran Become the Catalyst for a Major Stock Re-rating? | ||
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen |
Das Unternehmen GRI BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.